#FeatureFriday Members of Qanatpharma AG’s Swiss, German and Canadian team had a great strategic planning workshop this week in beautiful Lucerne to discuss our forthcoming Phase two clinical trial in heart failure as well as the recent growth of our project pipeline, which is harnessing the power of machine learning and AI to expedite development of next generation therapies targeting the microcirculation.